Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 3Active not recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 58Ovarian Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Advanced Breast Cancer 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Neoplasms by Site 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Advanced Solid Tumors 2Advanced Solid Tumor 2Unilateral Breast Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1HR+ Breast Cancer 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Fulvestrant × Clear all
NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NiKang Therapeutics, Inc.

Phase 1 Recruiting
361 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Pfizer

Phase 1 Recruiting
260 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡